{
 "drug": "Azacitidine Injection",
 "asOf": "2026-08-25",
 "status": "in-shortage",
 "since": "12/18/2020",
 "dayN": 2076,
 "cat": "Oncology",
 "companies": [
  "Fresenius Kabi USA, LLC",
  "Meitheal Pharmaceuticals, Inc.",
  "Dr. Reddy's Laboratories, Inc.",
  "Teva Pharmaceuticals USA, Inc.",
  "Accord Healthcare Inc.",
  "Hikma Pharmaceuticals USA, Inc.",
  "Armas Pharmaceuticals Inc",
  "Bristol Myers Squibb Co.",
  "Eugia US LLC"
 ],
 "reasons": [
  "Demand increase for the drug",
  "Other"
 ],
 "records": [
  {
   "update_type": "Revised",
   "initial_posting_date": "12/18/2020",
   "package_ndc": "63323-771-39",
   "generic_name": "Azacitidine Injection",
   "contact_info": "1-888-386-1300",
   "availability": "Unavailable",
   "related_info": "Estimated recovery: TBD",
   "openfda": {
    "application_number": [
     "ANDA207518"
    ],
    "brand_name": [
     "AZACITIDINE"
    ],
    "generic_name": [
     "AZACITIDINE"
    ],
    "manufacturer_name": [
     "Fresenius Kabi USA, LLC"
    ],
    "product_ndc": [
     "63323-771"
    ],
    "product_type": [
     "HUMAN PRESCRIPTION DRUG"
    ],
    "route": [
     "INTRAVENOUS",
     "SUBCUTANEOUS"
    ],
    "substance_name": [
     "AZACITIDINE"
    ],
    "rxcui": [
     "485246"
    ],
    "spl_id": [
     "4becda8d-8042-4cf1-bef3-c0ec3c23eebe"
    ],
    "spl_set_id": [
     "3b594aba-e798-4105-b801-0b0d970747c1"
    ],
    "package_ndc": [
     "63323-771-39"
    ],
    "nui": [
     "N0000000233",
     "N0000175595"
    ],
    "pharm_class_moa": [
     "Nucleic Acid Synthesis Inhibitors [MoA]"
    ],
    "pharm_class_epc": [
     "Nucleoside Metabolic Inhibitor [EPC]"
    ],
    "unii": [
     "M801H13NRU"
    ]
   },
   "update_date": "08/04/2026",
   "therapeutic_category": [
    "Oncology"
   ],
   "dosage_form": "Injection",
   "presentation": "Azacitidine, Injection, 100 mg/30 mL (NDC 63323-771-39)",
   "company_name": "Fresenius Kabi USA, LLC",
   "shortage_reason": "Demand increase for the drug",
   "status": "Current"
  },
  {
   "update_type": "Reverified",
   "initial_posting_date": "12/18/2020",
   "package_ndc": "71288-115-30",
   "generic_name": "Azacitidine Injection",
   "contact_info": "844-824-8426",
   "availability": "Available",
   "openfda": {
    "application_number": [
     "ANDA212128"
    ],
    "brand_name": [
     "AZACITIDINE"
    ],
    "generic_name": [
     "AZACITIDINE"
    ],
    "manufacturer_name": [
     "Meitheal Pharmaceuticals Inc."
    ],
    "product_ndc": [
     "71288-115"
    ],
    "product_type": [
     "HUMAN PRESCRIPTION DRUG"
    ],
    "route": [
     "INTRAVENOUS",
     "SUBCUTANEOUS"
    ],
    "substance_name": [
     "AZACITIDINE"
    ],
    "rxcui": [
     "485246"
    ],
    "spl_id": [
     "bad343f5-0c12-47de-93e7-9b2af3670b7c"
    ],
    "spl_set_id": [
     "97b0917a-03fa-4cc4-91cf-1bed57a988c9"
    ],
    "package_ndc": [
     "71288-115-30"
    ],
    "nui": [
     "N0000000233",
     "N0000175595"
    ],
    "pharm_class_moa": [
     "Nucleic Acid Synthesis Inhibitors [MoA]"
    ],
    "pharm_class_epc": [
     "Nucleoside Metabolic Inhibitor [EPC]"
    ],
    "unii": [
     "M801H13NRU"
    ]
   },
   "update_date": "06/01/2026",
   "therapeutic_category": [
    "Oncology"
   ],
   "dosage_form": "Injection",
   "presentation": "Azacitidine, Injection, 100 mg/30 mL (NDC 71288-115-30)",
   "company_name": "Meitheal Pharmaceuticals, Inc.",
   "status": "Current"
  },
  {
   "update_type": "Reverified",
   "initial_posting_date": "12/18/2020",
   "package_ndc": "43598-305-62",
   "generic_name": "Azacitidine Injection",
   "contact_info": "866-732-3952",
   "availability": "Available",
   "related_info": "Available to existing customers",
   "openfda": {
    "application_number": [
     "ANDA201537"
    ],
    "brand_name": [
     "AZACITIDINE"
    ],
    "generic_name": [
     "AZACITIDINE"
    ],
    "manufacturer_name": [
     "Dr. Reddy's Laboratories Inc."
    ],
    "product_ndc": [
     "43598-305"
    ],
    "product_type": [
     "HUMAN PRESCRIPTION DRUG"
    ],
    "route": [
     "INTRAVENOUS",
     "SUBCUTANEOUS"
    ],
    "substance_name": [
     "AZACITIDINE"
    ],
    "rxcui": [
     "485246"
    ],
    "spl_id": [
     "35e92030-ae2f-04b2-c3de-69f8c8da6b82"
    ],
    "spl_set_id": [
     "71d8d758-86c9-b571-aed1-719654fd4b82"
    ],
    "package_ndc": [
     "43598-305-62"
    ],
    "nui": [
     "N0000000233",
     "N0000175595"
    ],
    "pharm_class_moa": [
     "Nucleic Acid Synthesis Inhibitors [MoA]"
    ],
    "pharm_class_epc": [
     "Nucleoside Metabolic Inhibitor [EPC]"
    ],
    "unii": [
     "M801H13NRU"
    ]
   },
   "update_date": "08/05/2026",
   "therapeutic_category": [
    "Oncology"
   ],
   "dosage_form": "Injection",
   "presentation": "Azacitidine, Injection, 100 mg (NDC 43598-305-62)",
   "company_name": "Dr. Reddy's Laboratories, Inc.",
   "status": "Current"
  },
  {
   "update_type": "Revised",
   "initial_posting_date": "12/22/2020",
   "package_ndc": "68001-313-56",
   "generic_name": "Azacitidine Injection",
   "contact_info": "800-545-8800",
   "availability": "Unavailable",
   "related_info": "Estimated recovery: TBD",
   "openfda": {
    "application_number": [
     "NDA208216"
    ],
    "brand_name": [
     "AZACITIDINE"
    ],
    "generic_name": [
     "AZACITIDINE"
    ],
    "manufacturer_name": [
     "BluePoint Laboratories"
    ],
    "product_ndc": [
     "68001-313"
    ],
    "product_type": [
     "HUMAN PRESCRIPTION DRUG"
    ],
    "route": [
     "INTRAVENOUS",
     "SUBCUTANEOUS"
    ],
    "substance_name": [
     "AZACITIDINE"
    ],
    "rxcui": [
     "485246"
    ],
    "spl_id": [
     "36080e4e-a0fe-ba15-e063-6394a90aed5c"
    ],
    "spl_set_id": [
     "5f0f9ee3-a5b1-4a25-a34c-7f38c8433f4a"
    ],
    "package_ndc": [
     "68001-313-56"
    ],
    "nui": [
     "N0000000233",
     "N0000175595"
    ],
    "pharm_class_moa": [
     "Nucleic Acid Synthesis Inhibitors [MoA]"
    ],
    "pharm_class_epc": [
     "Nucleoside Metabolic Inhibitor [EPC]"
    ],
    "unii": [
     "M801H13NRU"
    ]
   },
   "update_date": "08/17/2026",
   "therapeutic_category": [
    "Oncology"
   ],
   "dosage_form": "Injection",
   "presentation": "Azacitidine, Injection, 100 mg (NDC 68001-313-56)",
   "company_name": "Teva Pharmaceuticals USA, Inc.",
   "shortage_reason": "Other",
   "status": "Current"
  },
  {
   "update_type": "Reverified",
   "initial_posting_date": "12/21/2020",
   "package_ndc": "16729-306-10",
   "generic_name": "Azacitidine Injection",
   "contact_info": "866-941-7875, option 2",
   "availability": "Available",
   "openfda": {
    "application_number": [
     "ANDA207475"
    ],
    "brand_name": [
     "AZACITIDINE"
    ],
    "generic_name": [
     "AZACITIDINE"
    ],
    "manufacturer_name": [
     "Accord Healthcare Inc."
    ],
    "product_ndc": [
     "16729-306"
    ],
    "product_type": [
     "HUMAN PRESCRIPTION DRUG"
    ],
    "route": [
     "INTRAVENOUS",
     "SUBCUTANEOUS"
    ],
    "substance_name": [
     "AZACITIDINE"
    ],
    "rxcui": [
     "485246"
    ],
    "spl_id": [
     "28604daf-46a3-ef6c-e063-6394a90a4b27"
    ],
    "spl_set_id": [
     "70140e11-33f1-2240-e053-2991aa0a0480"
    ],
    "package_ndc": [
     "16729-306-10"
    ],
    "nui": [
     "N0000000233",
     "N0000175595"
    ],
    "pharm_class_moa": [
     "Nucleic Acid Synthesis Inhibitors [MoA]"
    ],
    "pharm_class_epc": [
     "Nucleoside Metabolic Inhibitor [EPC]"
    ],
    "unii": [
     "M801H13NRU"
    ]
   },
   "update_date": "08/17/2026",
   "therapeutic_category": [
    "Oncology"
   ],
   "dosage_form": "Injection",
   "presentation": "Azacitidine, Injection, 100 mg (NDC 16729-306-10)",
   "company_name": "Accord Healthcare Inc.",
   "status": "Current"
  },
  {
   "update_type": "Reverified",
   "initial_posting_date": "12/18/2020",
   "package_ndc": "0143-9606-01",
   "generic_name": "Azacitidine Injection",
   "contact_info": "1-800-631-2174",
   "availability": "Available",
   "related_info": "Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.",
   "openfda": {
    "application_number": [
     "ANDA209337"
    ],
    "brand_name": [
     "AZACITIDINE"
    ],
    "generic_name": [
     "AZACITIDINE"
    ],
    "manufacturer_name": [
     "Hikma Pharmaceuticals USA Inc."
    ],
    "product_ndc": [
     "0143-9606"
    ],
    "product_type": [
     "HUMAN PRESCRIPTION DRUG"
    ],
    "route": [
     "INTRAVENOUS",
     "SUBCUTANEOUS"
    ],
    "substance_name": [
     "AZACITIDINE"
    ],
    "rxcui": [
     "485246"
    ],
    "spl_id": [
     "592a688f-2e42-4e91-a3ea-34befe2a4e07"
    ],
    "spl_set_id": [
     "ff73515d-bd55-4eb5-992b-d2138c80887e"
    ],
    "package_ndc": [
     "0143-9606-01"
    ],
    "nui": [
     "N0000000233",
     "N0000175595"
    ],
    "pharm_class_moa": [
     "Nucleic Acid Synthesis Inhibitors [MoA]"
    ],
    "pharm_class_epc": [
     "Nucleoside Metabolic Inhibitor [EPC]"
    ],
    "unii": [
     "M801H13NRU"
    ]
   },
   "update_date": "08/13/2026",
   "therapeutic_category": [
    "Oncology"
   ],
   "dosage_form": "Injection",
   "presentation": "Azacitidine, Injection, 100 mg/ Vial (NDC 0143-9606-01)",
   "company_name": "Hikma Pharmaceuticals USA, Inc.",
   "status": "Current"
  },
  {
   "update_type": "Revised",
   "initial_posting_date": "12/18/2020",
   "package_ndc": "72485-201-01",
   "generic_name": "Azacitidine Injection",
   "contact_info": "732-637-1971",
   "availability": "Limited Availability",
   "related_info": "Estimated recovery: TBD",
   "openfda": {
    "application_number": [
     "ANDA207518"
    ],
    "brand_name": [
     "AZACITIDINE"
    ],
    "generic_name": [
     "AZACITIDINE"
    ],
    "manufacturer_name": [
     "Armas Pharmaceuticals Inc."
    ],
    "product_ndc": [
     "72485-201"
    ],
    "product_type": [
     "HUMAN PRESCRIPTION DRUG"
    ],
    "route": [
     "INTRAVENOUS",
     "SUBCUTANEOUS"
    ],
    "substance_name": [
     "AZACITIDINE"
    ],
    "rxcui": [
     "485246"
    ],
    "spl_id": [
     "ca345575-17a6-43a3-aa02-3d4bb9d136c5"
    ],
    "spl_set_id": [
     "5c0a2d5f-8c34-4c04-8425-7543965cedd4"
    ],
    "package_ndc": [
     "72485-201-01"
    ],
    "nui": [
     "N0000000233",
     "N0000175595"
    ],
    "pharm_class_moa": [
     "Nucleic Acid Synthesis Inhibitors [MoA]"
    ],
    "pharm_class_epc": [
     "Nucleoside Metabolic Inhibitor [EPC]"
    ],
    "unii": [
     "M801H13NRU"
    ]
   },
   "update_date": "06/08/2026",
   "therapeutic_category": [
    "Oncology"
   ],
   "dosage_form": "Injection",
   "presentation": "Azacitidine, Injection, 100 mg (NDC 72485-201-01)",
   "company_name": "Armas Pharmaceuticals Inc",
   "shortage_reason": "Other",
   "status": "Current"
  },
  {
   "update_type": "Reverified",
   "initial_posting_date": "12/18/2020",
   "package_ndc": "59572-102-01",
   "generic_name": "Azacitidine Injection",
   "contact_info": "1-888-423-5436",
   "availability": "Available",
   "openfda": {
    "application_number": [
     "NDA050794"
    ],
    "brand_name": [
     "VIDAZA"
    ],
    "generic_name": [
     "AZACITIDINE"
    ],
    "manufacturer_name": [
     "Celgene Corporation"
    ],
    "product_ndc": [
     "59572-102"
    ],
    "product_type": [
     "HUMAN PRESCRIPTION DRUG"
    ],
    "route": [
     "INTRAVENOUS",
     "SUBCUTANEOUS"
    ],
    "substance_name": [
     "AZACITIDINE"
    ],
    "rxcui": [
     "485246",
     "545206"
    ],
    "spl_id": [
     "8cba79e2-11fa-4eb9-87e7-827ca781fbf3"
    ],
    "spl_set_id": [
     "3495a71a-cc04-4776-851f-f185956f32af"
    ],
    "package_ndc": [
     "59572-102-01"
    ],
    "nui": [
     "N0000000233",
     "N0000175595"
    ],
    "pharm_class_moa": [
     "Nucleic Acid Synthesis Inhibitors [MoA]"
    ],
    "pharm_class_epc": [
     "Nucleoside Metabolic Inhibitor [EPC]"
    ],
    "unii": [
     "M801H13NRU"
    ]
   },
   "update_date": "08/16/2026",
   "therapeutic_category": [
    "Oncology"
   ],
   "dosage_form": "Injection",
   "presentation": "Vidaza, Injection, 100 mg (NDC 59572-102-01)",
   "company_name": "Bristol Myers Squibb Co.",
   "status": "Current"
  },
  {
   "update_type": "Reverified",
   "initial_posting_date": "12/22/2020",
   "package_ndc": "55150-393-01",
   "generic_name": "Azacitidine Injection",
   "contact_info": "888-238-7880",
   "availability": "Unavailable",
   "related_info": "On backorder. Recovery: TBD. Check wholesalers for inventory",
   "openfda": {
    "application_number": [
     "ANDA215066"
    ],
    "brand_name": [
     "AZACITIDINE"
    ],
    "generic_name": [
     "AZACITIDINE"
    ],
    "manufacturer_name": [
     "Eugia US LLC"
    ],
    "product_ndc": [
     "55150-393"
    ],
    "product_type": [
     "HUMAN PRESCRIPTION DRUG"
    ],
    "route": [
     "INTRAVENOUS",
     "SUBCUTANEOUS"
    ],
    "substance_name": [
     "AZACITIDINE"
    ],
    "rxcui": [
     "485246"
    ],
    "spl_id": [
     "e89b9510-86df-4095-b6d3-4eb05b613c4f"
    ],
    "spl_set_id": [
     "ecd108bd-bb5f-4b2e-ad91-210fca452e9b"
    ],
    "package_ndc": [
     "55150-393-01"
    ],
    "nui": [
     "N0000000233",
     "N0000175595"
    ],
    "pharm_class_moa": [
     "Nucleic Acid Synthesis Inhibitors [MoA]"
    ],
    "pharm_class_epc": [
     "Nucleoside Metabolic Inhibitor [EPC]"
    ],
    "unii": [
     "M801H13NRU"
    ]
   },
   "update_date": "08/06/2026",
   "therapeutic_category": [
    "Oncology"
   ],
   "dosage_form": "Injection",
   "presentation": "Azacitidine, Injection, 100 mg/4 mL (NDC 55150-393-01)",
   "company_name": "Eugia US LLC",
   "shortage_reason": "Demand increase for the drug",
   "status": "Current"
  }
 ]
}